

Title:

Delegation and/or Medical Directive

Eye Prophylaxis in the Newborn

Policy Number:	06-02			
Approval Date:	February 2019			
Review Date:	Annually			
Review Due Date:				
Sponsoring Person:	Chief of Department of Paediatrics, QHC BGH			
Does this policy include a delegation of a controlled act? ☐ Yes ■ No				
Orders:		Appendix Attached: □ Yes ■ No Title:		
The authorized Nurses in the Quinte Healthcare Corporation (QHC) may perform the Medical Directive provided the requirements, as listed in the directive, are met. If the appropriate physician or health care provider with ordering authority is not immediately available to provide the order, the nurse caring for the newborn infant at Quinte Healthcare may administer erythromycin ointment 0.5% to both eyes of the neonate.				
Recipient Patients:		Appendix Attached: ☐ Yes ■ No Title:		
Newborn infant in the Quinte Healthcare Corporation (QHC).				
Approving Physician(s)/ Authorizer(s):		Appendix Attached: ■ Yes □ No Title: Appendix 1: Designated Physician Authorization Sheet		
Ensure a signed copy of approvals is maintained with the Medical Directives on the unit, Medical Directive Manual (Patient Services), and Chief of Staff office.				



Delegation and/or Medical Directive

Authorized Implementers:	Appendix Attached: ■ Yes □ No Title: Appendix 2 Authorized Implementer Form Appendix 3: Self - Learning Package Appendix 4: Self Appraisal of Competency Statement for Authorized Staff		
 All Quinte Healthcare nurses, who have: Completed the Self - Learning Package or attended an education session and have reviewed the Medical Directive annually (See Appendix 3 – "Self - Learning Package"). Completed the Self Appraisal of Competency Statement form and submitted to the manager, clinical educator or designate (See Appendix 4 – "Self Appraisal of Competency Statement for Authorized Staff"). 			
Indicators:	Appendix Attached: ■ Yes □ No		
	Title: Appendix 3: Self - Learning Package		
 Erythromycin ointment is a recognized prophylaxis for gonococcal and chlamydial ophthalmia neonatorum. The administration of a prophylactic agent to the newborn infant's eyes is legislated under Section 33 and Regulation 557 health Promotion and Protection Act, exemptions may be granted only if the criteria outlined in the legislation is met (See Appendix 3 – "Self - Learning Package" and policy 3.15.7 - Maternal/Child – Ophthalmia Neonatorum Prophylaxis). Erythromycin ointment should be instilled within one hour after delivery or as soon thereafter as is practicable (Regulation 557). 			
Contraindications:	Appendix Attached: □ Yes ■ No Title:		
Parent/legal guardian/substitute decision maker has requested an exemption and meets the criteria for exemption (Refer to Policy 3.15.7 - Maternal/Child – Ophthalmia Neonatorum Prophylaxis).			
Consent:	Appendix Attached: □ Yes ■ No Title:		
The patient is registered at QHC. Parent/legal guardian/substitute decision has given verbal consent (Refer to Policy 3.15.7).			



Delegation and/or Medical Directive

Guidelines for Implementing the Order/Procedure:	Appendix Attached: ■ Yes □ No Title:		
Order/Trocedure.	Appendix 5: Implementing a Medical Directive		
> If needed, initial resuscitation me			
Documentation and Communication:	Appendix Attached: ☐ ■ Yes No Title: Appendix 6: Ophthalmia Neonatorum Prophylaxis Directive Order Set		
assessments, treatments, and patient r	y and CNO standards, the nurse will document the appropriate responses and outcomes, and ensure the directive is attorum Prophylaxis Directive Order Set.Administration of this e MAR.		
Review and Quality Monitoring Guidelines	Appendix Attached: ■ Yes □ No Title: Appendix 4: Self Appraisal of Competency Statement for Authorized Staff		
years, either on the Unit or at a design Staff identifying any untoward or uni	Educator or designate) will supervise the clinical component every 2 nated education session. Intended outcomes arising from implementation of orders under this h it will report these to the manager as soon as possible for appropriate		
1	toward or unintended outcomes or issues that are possible clinical		
Administrative Approvals:	Appendix Attached: ☐ Yes ■ No Title:		



Delegation and/or Medical Directive

Date of Pharmacy and Therapeutics Committee Appr	oval: October 2015				
Date of Maternal/Child Care Program Advisory Com	mittee Approval: February 21, 2019				
Date of MAC Approval:					
Ensure a signed copy of approval is maintained with the medical directive manual coordinator, and with the Chief of Staff office.					
Chief of Staff	Chief Nursing Executive				
Date	Date				

References:

Canadian Paediatric Society (CPS) (2015). Preventing ophthalmia neonatorum [Position Statement]. *Paediatrics and Child Health*, 20 (2), p. 93 – 96. http://www.cps.ca

College of Nurses of Ontario. (2004). *Directives. [Practice Guideline: Revised 2014]*. Toronto, ON: Author. www.cno.org

Evans, R. J., Evans, M. K., Brown, Y. M. & Orshan, S. A. (2010). *Canadian maternity, newborn and women's health nursing*. Philadelphia, PA: Wolters Kluwer | Lippincott Williams & Wilkins.

Health Protection and Promotion Act, R.S.O, Regulation 557 Communicable Diseases.

Mabry-Hernandez, I. & Oliverio-Hoffman, R. (2010). *Ocular prophylaxis for Gonococcal ophthalmia neonatorum.* U.S. Preventative Task Force [Recommendation Statement] AHRQ Publication No. 10-05146

Matejcek, A. & Goldman, R. D. (2013). Treatment and Prevention of ophthalmia neonatorum. *Canadian Family Physician* 59. P. 1187 – 1190

Schaller, U. C. & Klauss, V. (2001). Is Credé's prophylaxis for ophthalmia neonatorum still valid? [Bulletin of the World Health Organization] Ref. No. 00-1032

Appendices:

Appendix 1: Designated Physician Authorization Sheet

Appendix 2: Authorized Implementer Form

Appendix 3: Self – Learning Package

Appendix 4: Self – Appraisal of Competency Statement for Authorized Staff

Appendix 5: Implementing a Medical Directive

Appendix 6: Ophthalmia Neonatorum Prophylaxis Directive Order Set